How much does Taltz (Ixekizumab Injection) Cost& price without insurance in China?
Taltz® is the commercial brand name of Ixekizumab Injection, a humanized anti-IL-17A monoclonal antibody developed by Eli Lilly. It selectively binds to interleukin 17A (IL-17A), inhibiting its interaction with the IL-17 receptor and blocking the inflammatory cascade in autoimmune diseases.
Main Indications
Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Treatment of active psoriatic arthritis in adult patients, alone or in combination with methotrexate.
Treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
Common Side Effects
Common mild adverse reactions: Upper respiratory tract infections, injection site reactions, headache, and nausea.
Severe but uncommon risks: Serious infections (including tuberculosis and fungal infections), inflammatory bowel disease exacerbation, and hypersensitivity reactions.
Approval Status in China
Taltz® (Ixekizumab Injection, 80 mg/mL) was officially approved for marketing in China in 2019. It is currently a prescription biologic drug included in China’s Category B medical insurance.
Buy Taltz (Ixekizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
